DTx Last Mile Delivery: Adoption by HCPs and Patients

While the DTx market is growing exponentially, the scale of usage from the physician and patient cohorts remains low.  Despite proven clinical outcomes, regulatory approvals, usage and spread remains slim. For example, even though German DiGA has 19 approved products so far, their prescription and adoption have not taken off yet. Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx; we will talk about: